Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 1, 2010, Pages

  Nkansah, Nancy ^a   Mostovetsky, Olga ^a   Yu, Christine ^a   Chheng, Tami ^a   Beney, Johnny ^b   Bond, Christine M ^c   Bero, Lisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Institut Central des Hopitaux Valaisans   (Switzerland)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

AMBULATORY CARE; CLINICAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT EDUCATION; PHARMACIST; PHARMACY; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AMBULATORY CARE; COMMUNITY PHARMACY SERVICES; DELIVERY OF HEALTH CARE; HUMANS; HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PROFESSIONAL ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955491466     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000336.pub2     Document Type: Review

References (182)

1. Barbanel D, Eldridge S, Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. Thorax 2003;58(10):851-4.
2. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. Journal of General Internal Medicine 1997;12(3):158-64.
3. Bond C, Matheson C, Williams S, Williams P, Donnan P. Repeat prescribing: A role for community pharmacists in controlling and monitoring repeat prescriptions. British Journal of General Practice 2000;50(453):271-5.
4. Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, et al. Physician-pharmacist co management of hypertension: A randomised, comparative trial. Pharmacotherapy 2003;23(2):209-16.
5. Brook OH, Van Hout HP, Nieuwenhuysea H, De Haan M. Effects of coaching by community pharmacists on psychological symptoms of antidepressant users: A randomised controlled trial. European Neuropsychopharmacology 2003;13(5):347-54.
6. Boudreau DM, Capoccia KL, Sullivan SD, Blough DK, Ellsworth AJ, Clark DL, et al. Collaborative care model to improve outcomes in major depression. Annals of Pharmacotherapy 2002;36(4):585-91.
7. Capoccia KL, Boudreau DM, Blough DK, Ellsworth AJ, Clark DR, Stevens NG, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. American Journal of Health-System Pharmacy 2004;61(4):364-72.
8. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: A randomised controlled trial. American Journal of Managed Care 2005;11(4):253-60.
9. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2005;28(4):771-6.
10. Cody M, McCombs JS, Parker JP. The Kaiser Permanente/USC Patient Consultation Study: change in quality of life. University of Southern California. American Journal of Health-System Pharmacy 1998;55(24):2615-20. [MEDLINE: 99087735]
11. McCombs JS, Liu G, Shi J, Feng W, Cody M, Parker JP, et al. The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. American Journal of Health-System Pharmacy 1998;55(23):2485-99. [MEDLINE: 99068522]
12. Diwan VK, Wahlstrom R, Tomson G, Beermann B, Sterky G, Eriksson B. Effects of "group detailing" on the prescribing of lipid-lowering drugs: a randomised controlled trial in Swedish primary care. Journal of Clinical Epidemiology 1995;48(5):705-11. [MEDLINE: 95248412]
13. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, et al. Impact of a collaborative care model on depression in a primary care setting: A randomized controlled trial. Pharmacotherapy 2003;23(9):1175-85.
14. Freemantle N, Nazareth I, Eccles M, Wood J, Haines A. A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice. British Journal of General Practice 2002;52(477):290-5.
15. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Archives of Internal Medicine 1999;159(16):1939-45.
16. Gonzalez-Martin G, Joo I, Sanchez I. Evaluation of the impact of a pharmaceutical care program in children with asthma. Patient Education and Counselling 2003;49(1):13-8.
17. Goodyer LI, Miskelly F, Milligan P. Does encouraging good compliance improve patients' clinical condition in heart failure?. British Journal of Clinical Practice 1995;49(4):173-6. [MEDLINE: 96004938]
18. Hall L, Eccles M, Barton R, Steen N, Campbell M. Is untargeted outreach visiting in primary care effective? A pragmatic randomized controlled trial. Journal of Public Health Medicine 2001;23(2):109-13.
19. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. American Journal of Medicine 1996;100(4):428-37. [MEDLINE: 96194605]
20. Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. American Journal of Hospital Pharmacy 1979;36(10):1321-5. [MEDLINE: 80062510]
21. Ilett KF, Johnson S, Greenhill G, Mullen L, Brockis J, Golledge CL, et al. Modification of general practitioner prescribing of antibiotics by use of a therapeutics adviser (academic detailer). British Journal of Clinical Pharmacology 2000;49(2):168-73.
22. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Annals of Pharmacotherapy 1996;30(3):238-43. [MEDLINE: 96430432]
23. Jackson SL, Peterson GM, Vial JH, Jupe DM. Improving the outcomes of anticoagulation: An evaluation of home follow-up of warfarin initiation. Journal of Internal Medicine 2004;256(2):137-44.
24. Jameson J, VanNoord G, Vanderwoud K. The impact of a pharmacotherapy consultation on the cost and outcome of medical therapy. Journal of Family Practice 1995;41(5):469-72. [MEDLINE: 96067264]
25. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20(12):1508-16.
26. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems?. Medical Care 2001;39(2):113-22.
27. Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy 2000;20(11):1384-9.
28. Meredith S, Feldman P, Frey D, Giammarco L, Hall K, Arnold K, et al. Improving medication use in newly admitted home healthcare patients: A randomized controlled trial. Journal of the American Geriatrics Society 2002;50(9):1484-91.
29. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: A randomised pharmacist intervention. Annals of Pharmacotherapy 2005;39(3):433-40.
30. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy 2001;21(11):1337-44.
31. Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting. Journal of the American Pharmaceutical Association 1996;NS36(7):443-51.
32. Paulos CP, Nygren CE, Celedon C, Carcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Annals of Pharmacotherapy 2005;39(5):939-43.
33. Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. Journal of Clinical Pharmacy and Therapeutics 2004;29(1):23-30.
34. Rickles NM, Svarstad BL, Statz-Paynter JL, Taylor LV, Kobak KA. Pharmacist telemonitoring of antidepressant use: Effects on pharmacist-patient collaboration. Journal of the American Pharmacists Association 2005;45(3):344-53.
35. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. British Journal of Clinical Pharmacology 2005;60(2):183-93.
36. Sarkadi A, Rosenqvist U. Experience-based group education in Type 2 diabetes: A randomised controlled trial. Patient Education and Counseling 2004;53(3):291-8.
37. Schneider PJ, Larrimer JN, Visconti JA, Miller WA. Role effectiveness of a pharmacist in the maintenance of patients with hypertension and congestive heart failure. Contemporary Pharmacy Practice 1982;5(2):74-9.
38. Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. Journal of the American Pharmacists Association 1998;38(5):574-85.
39. Sookaneknun P, Richards RM, Sanguansermsri J, Teerasut C. Pharmacist involvement in primary care improves hypertensive patient clinical outcomes. Annals of Pharmacotherapy 2004;38(12):2023-8.
40. Stergachis A, Fors M, Wagner EH, Sims DD, Penna P. Effect of clinical pharmacists on drug prescribing in a primary-care clinic. American Journal of Hospital Pharmacy 1987;44(3):525-9. [MEDLINE: 87181708]
41. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. American Journal of Health-System Pharmacy 2003;60(11):1123-9.
42. Tsuyuki RT, Johnson JA, Teo KK, Ackman ML, Biggs RS, Cave A, et al. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Annals of Pharmacotherapy 1999;33(9):910-9.
43. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Archives of Internal Medicine 2002;162(10):1149-55.
44. Turner CJ, Parfrey P, Ryan K, Miller R, Brown A. Community pharmacist outreach program directed at physicians treating congestive heart failure. American Journal of Health-System Pharmacy 2000;57(8):747-52.
45. Van Veldhuizen-Scott MK, Widmer LB, Stacey SA, Popovich NG. Developing and implementing a pharmaceutical care model in an ambulatory care setting for patients with diabetes. Diabetes Educator 1995;21(2):117-23. [MEDLINE: 95212208]
46. Watson M, Gunnell D, Peters T, Brookes S, Sharp D. Guidelines and educational outreach visits from community pharmacists to improve prescribing in general practice: A randomised controlled trial. Journal of Health Services Research and Policy 2001;6(4):207-13.
47. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, et al. Effectiveness of pharmacist care for patients with reactive airways disease: A randomized controlled trial. JAMA 2002;288(13):1594-602.
48. Abramowitz PW, Nold EG, Hatfield SM. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs. American Journal of Hospital Pharmacy 1982;39(7):1176-80.
49. Bogden PE, Abbott RD, Williamson P, Onopa JK, Koontz LM. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. Journal of General Internal Medicine 1998;13(11):740-5.
50. Bolas H, Brookes K, Scott M, McElnay J. Evaluation of a hospital-based community liaison pharmacy service in Northern Ireland. Pharmacy World and Science 2004;26(2):114-20.
51. Bouvy ML, Heerdink ER, Urquhart J, Grobbee DE, Hoes AW, Leufkens HG. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: A randomized controlled study. Journal of Cardiac Failure 2003;9(5):404-11.
52. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20(11):1375-83.
53. Brook O, van Hout H, Nieuwenhuyse H, Heerdink E. Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients: A randomized controlled trial. European Neuropsychopharmacology 2003;13(1):1-9.
54. Brook OH, van Hout H, Stalman W, Nieuwenhuyse H, Bakker B, Heerdink E, et al. A pharmacy-based coaching program to improve adherence to antidepressant treatment among primary care patients. Psychiatric Services 2005;56(4):487-9.
55. Bucci C, Jackevicius C, McFarlane K, Liu P. Pharmacist's contribution in a heart function clinic: Patient perception and medication appropriateness. Canadian Journal of Cardiology 2003;19(4):391-6.
56. Charrois T, Newman S, Sin D, Senthilselvan A, Tsuyuki RT. Improving asthma symptom control in rural communities: The design of the Better Respiratory Education and Asthma Treatment in Hinton and Edson study. Controlled Clinical Trials 2004;25(5):502-14.
57. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clinical Transplantation 2001;15(5):330-6.
58. Cowper PA, Weinberger M, Hanlon JT, Landsman PB, Samsa GP, Uttech KM, et al. The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy 1998;18(2):327-32.
59. Davidson MB, Karlan VJ, Hair TL. Effect of a pharmacist-managed diabetes care program in a free medical clinic. American Journal of Medical Quality 2000;15(4):137-42.
60. de Maat MM, de Boer A, Koks CH, Mulder JW, Meenhorst PL, van Gorp EC, et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Journal of Clinical Pharmacy and Therapeutics 2004;29(2):121-30.
61. De Tullio PL, Kirking DM, Arslanian C, Olson DE. Compliance measure development and assessment of theophylline therapy in ambulatory patients. Journal of Clinical Pharmacy and Therapeutics 1987;12(1):19-26. [MEDLINE: 88213490]
62. De Tullio PL, Corson ME. Effect of pharmacist counselling on ambulatory patients' use of aerosolized bronchodilators. American Journal of Hospital Pharmacy 1987;44(8):1802-6. [MEDLINE: 87323268]
63. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17(1):140-7. [MEDLINE: 97170246]
64. Fischer LR, Defor TA, Cooper S, Scott LM, Boonstra DM, Eelkema MA, et al. Pharmaceutical care and health care utilization in an HMO. Effective Clinical Practice 2002;5(2):49-57.
65. Fornos Perez JA, Guerra Garcia MM, Andres Rodriguez NF, Egea Ibernon B. [Evaluation of a programme to monitor drug therapy in type-2 diabetics]. Atencion Primaria 2004;34(1):48-54.
66. Forstrom MJ, Ried LD, Stergachis AS, Corliss DA. Effect of a clinical pharmacist program on the cost of hypertension treatment in an HMO family practice clinic. DICP 1990;24(3):304-9.
67. Garnett WR, Davis LJ, McKenney JM, Steiner KC. Effect of telephone follow-up on medication compliance. American Jounal of Hospital Pharmacy 1981;38(5):676-9. [MEDLINE: 82021105]
68. Gourley GA, Portner TS, Gourley DR, Rigolosi EL, Holt JM, Solomon DK, et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. Journal of the American Pharmaceutical Association 1998;38(5):586-97.
69. Helling DK, Hepler CD, Jones ME. Effect of direct clinical pharmaceutical services on patients' perceptions of health care quality. American Journal of Hospital Pharmacy 1979;36(3):325-9. [MEDLINE: 79121929]
70. Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 2005;330(7486):293.
71. Ibrahim OM, Catania PN, Mergener MA, Supernaw RB. Outcome of cholesterol screening in a community pharmacy. DICP 1990;24(9):817-21. [MEDLINE: 91082517]
72. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Annals of Pharmacotherapy 2001;35(7-8):835-40.
73. Johnson KA, Parker JP, McCombs JS, Cody M. The Kaiser Permanente/USC Patient Consultation Study: patient satisfaction with pharmaceutical services. University of Southern California. American Journal of Health-System Pharmacy 1998;55(24):2621-9. [MEDLINE: 99087736]
74. Jones RA, Lopez LM, Beall DG. Cost-effective implementation of clinical pharmacy services in an ambulatory care clinic. Hospital Pharmacy 1991;26(9):778-82.
75. Karki SD, Chandra P, Holden JMC, Shehata H. Impact of team approach on reducing drug costs. International Journal of Geriatric Psychiatry 1988;3:89-93.
76. Knoell DL, Pierson JF, Marsh CB, Allen JN, Pathak DS. Measurement of outcomes in adults receiving pharmaceutical care in a comprehensive asthma outpatient clinic. Pharmacotherapy 1998;18(6):1365-74.
77. Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led medication review in patients over 65: A randomized, controlled trial in primary care. Age & Ageing 2001;30:205-11.
78. Lai LL. Effects of a pharmaceutical care intervention in primary care ambulatory settings among Medicaid population. Journal of Pharmaceutical Care 1998;2(2):1-13.
79. Law S, Wu W. Cost-savings from subsidized pro-active pharmacist interventions. Journal of Pharmacy and Pharmaceutical Sciences 2003;6(1):84-94.
80. Lim WS, Low HN, Chan SP, Chen HN, Ding YY, Tan TL. Impact of a pharmacist consult clinic on a hospital-based geriatric outpatient clinic in Singapore. Annals of the Academy of Medicine, Singapore 2004;33(2):220-7.
81. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: The IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20(10):1149-58.
82. Malone M, Alger-Mayer SA. Pharmacist intervention enhances adherence to orlistat therapy. Annals of Pharmacotherapy 2003;37(11):1598-602.
83. McKenney JM, Slining JM, Henderson HR, Devins D, Barr M. The effect of clinical pharmacy services on patients with essential hypertension. Circulation 1973;48(5):1104-11. [MEDLINE: 74028680]
84. Murray MD, Harris LE, Overhage JM, Zhou XH, Eckert GJ, Smith FE, et al. Failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated hypertension: Results of a randomized controlled trial. Pharmacotherapy 2004;24(3):324-37.
85. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, et al. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. American Journal of Geriatric Pharmacotherapy 2004;2:53-65.
86. Peterson GM, Sugden JE. Educational program to improve the dosage prescribing of allopurinol. Medical Journal of Australia 1995;162(2):74-7. [MEDLINE: 95139868]
87. Peterson GM, Bergin JK, Nelson BJ, Stanton LA. Improving drug use in rheumatic disorders. Journal of Clinical Pharmacy and Therapeutics 1996;21(4):215-20.
88. Peterson GM, Stanton LA, Bergin JK, Chapman GA. Improving the prescribing of antibiotics for urinary tract infection. Journal of Clinical Pharmacy and Therapeutics 1997;22(2):147-53. [MEDLINE: 98041148]
89. Powers DA, Hamilton CW, Roberts KB. Pharmacist intervention in methadone administration to cancer patients with chronic pain. American Journal of Hospital Pharmacy 1983;40(9):1520-3.
90. Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent prescribing in a health maintenance organization. American Journal of Hospital Pharmacy 1990;47(8):1766-73. [MEDLINE: 90358226]
91. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: A prospective, randomized, controlled pilot study. Clinical Therapeutics 2005;27(2):199-209.
92. Rodgers S, Avery AJ, Meechan D, Briant S, Geraghty M, Doran K, et al. Controlled trial of pharmacist intervention in general practice: The effect on prescribing costs. British Journal of General Practice 1999;49(446):717-20.
93. Rogers KC, Johnson GL, White DM, Becker DM. Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists. Hospital Pharmacy 1998;33:1102-1104 +1110.
94. Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic prescribing in office practice. A controlled trial of three educational methods. Journal of the American Medical Association 1983;250(13):1728-32. [MEDLINE: 83294912]
95. Sczupak CA, Conrad WF. Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. American Journal of Hospital Pharmacy 1977;34:1238-42.
96. Sellors C, Dalby DM, Howard M, Kaczorowski J, Sellors J. A pharmacist consultation service in community-based family practices: A randomized, controlled trial in seniors. Journal of Pharmacy Technology 2001;17:264-9.
97. Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003;169(1):17-22.
98. Shaw H, Mackie CA, Sharkie I. Evaluation of effect of pharmacy discharge planning on medication problems experienced by discharged acute admission mental health patients. International Journal of Pharmacy Practice 2000;8:144-53.
99. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Annals of Pharmacotherapy 1997;31(6):713-9. [MEDLINE: 97328164]
100. Sidel VW, Beizer JL, Lisi-Fazio D, Kleinmann K, Wenston J, Thomas C, et al. Controlled study of the impact of educational home visits by pharmacists to high-risk older patients. Journal of Community Health 1990;15(3):163-74. [MEDLINE: 90308016]
101. Simpson SH, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist intervention in cholesterol risk management: An evaluation of the study of cardiovascular risk intervention by pharmacists. Pharmacotherapy 2001;21(5):627-35.
102. Simpson SH, Johnson JA, Biggs RS, Tsuyuki RT. Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: A planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Pharmacotherapy 2004;24(3):389-94.
103. Smith DH, Fassett WE, Christensen DB. Washington State CARE Project: downstream cost changes associated with the provision of cognitive services by pharmacists. Journal of the American Pharmacists Association 1999;39(5):650-7.
104. Soumerai SB, Avorn J. Economic and policy analysis of university-based drug "detailing". Medical Care 1986;24(4):313-31.
105. Steele MA, Bess DT, Franse VL, Graber SE. Cost effectiveness of two interventions for reducing outpatient prescribing costs. DICP 1989;23(6):497-500. [MEDLINE: 89299726]
106. Tamai IY, Rubenstein LZ, Josephson KR, Yamauchi JA. Impact of computerized drug profiles and a consulting pharmacist on outpatient prescribing patterns: a clinical trial. Drug Intelligence and Clinical Pharmacy 1987;21(11):890-5. [MEDLINE: 88054589]
107. Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: Interventions and outcomes. Pharmacotherapy 1999;19(7):860-9.
108. Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiology and Drug Safety 2006;15(2):115-21.
109. Wandless I, Whitmore J. The effect of counseling by a pharmacist on drug compliance in elderly patients. Journal of Clinical and Hospital Pharmacy 1981;6(1):51-6. [MEDLINE: 82239828]
110. Yamada C, Johnson JA, Robertson P, Pearson G, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: Extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy 2005;25(1):110-5.
111. Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001;323(7325):1340-3.
112. Bond C. The MEDMAN study: A randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease." Family Practice. Family Practice 2007;24:189-200.
113. Bond CMA, Fish A, Porteous T, Reid J, Scott A, Antonazzo E. A randomised controlled trial of the effects of note-based medication review by community pharmacists on prescribing of cardiovascular drugs in general practice. International Journal of Pharmacy Practice 2007;15:39-46.
114. Cameron IM, Matheson CI, Bond CM, McNamee P, Lawrie T, Robinson A, et al. Pilot randomised controlled trial of community pharmacy administration of buprenorphine versus methadone. International Journal of Pharmacy Practice 2006;14:243-8.
115. Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. Journal of Clinical Hypertension 2008;10:260-71.
116. Carter BL, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, et al. Physician and pharmacist collaboration to improve blood pressure control. Archives of Internal Medicine 2009;169:1996-2002.
117. Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH. Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. British Journal of Clinical Pharmacology 2006;62:601-9.
118. Charrois LT, Newman CS, Senthilselvan A, Tsuyuki TR. Improving asthma control in the rural setting: The BREATHE (Better Respiratory Education and Asthma Treatment in Hinton and Edson) study. Canadian Pharmacists Journal 2006;139(4):44-50.
119. Chisholm MA, Mulloy LL, Jagadeesan M, Martin BC, DiPiro JT. Effect of clinical pharmacy services on the blood pressure of African-American renal transplant patients. Ethnicity and Disease 2002;12:392-7.
120. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001;21:1196-203.
121. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-6.
122. Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, et al. Improved therapeutic monitoring with several interventions: a randomized trial. Archives of Internal Medicine 2006;166:1848-54.
123. Fornos JA, Andres NF, Andres JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharmacy World and Science 2006;28:65-72.
124. Hay EM, Foster NE, Thomas E, Peat G, Phelan M, Yates HE, et al. Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomised trial. BMJ 2006;333:995.
125. Hennessy S, Leonard CE, Yang W, Kimmel SE, Townsend RR, Wasserstein AG, et al. Effectiveness of a two-part educational intervention to improve hypertension control: a cluster-randomized trial. Pharmacotherapy 2006;26:1342-7.
126. Kritikos V, Armour CL, Bosnic-Anticevich SZ. Interactive small-group asthma education in the community pharmacy setting: a pilot study. Journal of Asthma 2007;44:57-64.
127. Kwan Y, Fernandes OA, Nagge JJ, Wong GG, Huh JH, Hurn DA, et al. Pharmacist medication assessments in a surgical preadmission clinic. Archives of Internal Medicine 2007;167:1034-40.
128. Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farmacia Hospitalaria 2006;30:328-42.
129. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction 2001;96:325-31.
130. Murray DM, Young J, Hoke S, Wanzhu T, Weiner M, Morrow D, et al. Pharmacist intervention to improve medication adherence in heart failure. Annals of Internal Medicine 2007;146:714-25.
131. Raebel MA, Lyons EE, Chester EA, Bodily MA, Kelleher JA, Long CL, et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. Archives of Internal Medicine 2005;165:2395-401.
132. Raebel MA, Chester EA, Newsom EE, Lyons EE, Kelleher JA, Long C, et al. Randomized trial to improve laboratory safety monitoring of ongoing drug therapy in ambulatory patients. Pharmacotherapy 2006;26:619-26.
133. Raebel MA, Charles J, Dugan J, Carroll NM, Korner EJ, Brand DW, et al. Randomized trial to improve prescribing safety in ambulatory elderly patients. Journal of the American Geriatrics Society 2007;55:977-85.
134. Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW Jr. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. Journal of Vascular Surgery 2006;43:1205-10.
135. Reid F, Murray P, Storrie M. Implementation of a pharmacist-led clinic for hypertensive patients in primary care--a pilot study. Pharmacy World and Science 2005;27:202-7.
136. Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. American Journal of Medicine 2005;118:276-84.
137. Simon GE, VonKorff M, Rutter C, Wagner E. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care. BMJ 2000;320:550-4.
138. Stergachis A, Gardner JS, Anderson MT, Sullivan SD. Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference?. Journal of the American Pharmacists Association 2002;42:743-52.
139. Sturgess IK, McElnay JC, Hughes CM, Crealey G. Community pharmacy based provision of pharmaceutical care to older patients. Pharmacy World and Science 2003;25:218-26.
140. Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy 2002;22:1533-40.
141. Volume CI, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical care research and education project: patient outcomes. Journal of the American Pharmacists Association 2001;41:411-20.
142. Welschen I, Kuyvenhoven MM, Hoes AW, Verheij TJ. Effectiveness of a multiple intervention to reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised controlled trial. BMJ 2004;329:431.
143. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine 2007;8:573-84.
144. Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 2006;333:522.
145. Yuan Y, Hay JW, McCombs JS. Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. American Journal of Managed Care 2003;9:45-56.
146. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). Journal of General Internal Medicine 2005;20:1091-6.
147. Beney J, Bero L, Bond CM. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD000336. DOI: 10.1002/14651858.CD000336.
148. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. Journal of Public Health Medicine 2003;25(2):144-53. [PUBMED: 12848404]
149. Christensen DB, Farris KB. Pharmaceutical care in community pharmacies: practice and research in the US. The Annals of Pharmacotherapy 2006;40(7-8):1400-6. [PUBMED: 16868221]
150. Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy 2007;27(7):1040-51. [PUBMED: 17594210]
151. Donovan JL, Drake JA, Whittaker P, Tran MT. Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. Journal of Thrombosis and Thrombolysis 2006;22(1):23-30. [PUBMED: 16786229]
152. Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy 2003;23(12):1634-44. [PUBMED: 14695043]
153. Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults?. The American Journal of Geriatric Pharmacotherapy 2004;2(1):3-13. [PUBMED: 15555474]
154. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD000011. DOI: 10.1002/14651858.CD000011.pub3.
155. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. Journal of the American Pharmacists Association: JAPhA 2006;46(2):168-79; quiz 179-82. [PUBMED: 16602227]
156. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. British Journal of Clinical Pharmacology 2008;65(3):303-16. [PUBMED: 18093253]
157. Horn E, Jacobi J. The critical care clinical pharmacist: evolution of an essential team member. Critical Care Medicine 2006;34(3 Suppl):S46-S51. [PUBMED: 16477202]
158. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy 1996;16(4):708-14. [PUBMED: 8840383]
159. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Archives of internal medicine 2006;166(9):955-64. [PUBMED: 16682568]
160. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive care medicine 2003;29(5):691-8. [PUBMED: 12665997]
161. Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. Journal of Clinical Pharmacy and Therapeutics 2006;31(5):409-19. [PUBMED: 16958818]
162. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. The Annals of Pharmacotherapy 2007;41(11):1770-81. [PUBMED: 17925496]
163. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. The Annals of Pharmacotherapy 2007;41(10):1569-82. [PUBMED: 17712043]
164. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Seminars in Dialysis 2002;15(1):45-9. [PUBMED: 11874593]
165. McLean WM, MacKeigan LD. When does pharmaceutical care impact health outcomes? A comparison of community pharmacy-based studies of pharmaceutical care for patients with asthma. The Annals of Pharmacotherapy 2005;39(4):625-31. [PUBMED: 15741416]
166. O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD000409. DOI: 10.1002/14651858.CD000409.pub2.
167. Perez A, Doloresco F, Hoffman JM, Meek PD, Touchette DR, Vermeulen LC, et al. American College of Clinical Pharmacy. ACCP: economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy 2009;29(1):128.
168. Pickard AS, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. The Annals of Pharmacotherapy 1999;33(11):1167-72. [PUBMED: 10573313]
169. Pickard AS, Hung SY. An update on evidence of clinical pharmacy services' impact on health-related quality of life. The Annals of Pharmacotherapy 2006;40(9):1623-34. [PUBMED: 16912249]
170. Ponniah A, Anderson B, Shakib S, Doecke CJ, Angley M. Pharmacists' role in the post-discharge management of patients with heart failure: a literature review. Journal of Clinical Pharmacy and Therapeutics 2007;32(4):343-52. [PUBMED: 17635336]
171. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs and Aging 2003;20(11):817-32. [PUBMED: 12964888]
172. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Quality and Safety in Health Care 2006;15(1):23-31. [PUBMED: 16456206]
173. Sanghera N, Chan PY, Khaki ZF, Planner C, Lee KK, Cranswick NE, et al. Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review. Drug safety: an international journal of medical toxicology and drug experience 2006;29(11):1031-47. [PUBMED: 17061909]
174. Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services--1988-1995. The Publications Committee of the American College of Clinical Pharmacy. Pharmacotherapy 1996;16(6):1188-208. [MEDLINE: 97103623]
175. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23(1):113-32. [PUBMED: 12523470]
176. Simonson W, Hauser RA, Schapira AH. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. The Annals of Pharmacotherapy 2007;41(11):1842-9. [PUBMED: 17878397]
177. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. The Annals of Pharmacotherapy 1999;33(12):1336-55. [PUBMED: 10630834]
178. Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. The Annals of Pharmacotherapy 2000;34(11):1320-31. [PUBMED: 11098348]
179. van Eijken M, Tsang S, Wensing M, de Smet PA, Grol RP. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs and Aging 2003;20(3):229-40. [PUBMED: 12578402]
180. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. The Annals of pharmacotherapy 2005;39(2):319-28. [PUBMED: 15632223]
181. von Gunten V, Reymond JP, Beney J. Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review. Pharmacy World and Science 2007;29(3):146-63. [PUBMED: 17273907]
182. Westerlund LT, Bjork HT. Pharmaceutical care in community pharmacies: practice and research in Sweden. The Annals of Pharmacotherapy 2006;40(6):1162-9. [PUBMED: 16735653]